Neuroone Medical Technologies Corp NMTC
We take great care to ensure that the data presented and summarized in this overview for NEUROONE MEDICAL TECHNOLOGIES Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NMTC
View all-
Bleichroeder LP New York, NY4MShares$2.76 Million0.95% of portfolio
-
Sio Capital Management, LLC New York, NY2.36MShares$1.63 Million0.73% of portfolio
-
Bard Associates Inc Chicago, IL1.85MShares$1.28 Million0.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$1.09 Million0.0% of portfolio
-
Perkins Capital Management Inc1.47MShares$1.01 Million1.29% of portfolio
-
Awm Investment Company, Inc. New York, NY917KShares$632,5000.1% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny693KShares$477,8930.0% of portfolio
-
Geode Capital Management, LLC Boston, MA497KShares$342,8150.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il206KShares$142,3310.0% of portfolio
-
Cambridge Investment Research Advisors, Inc.121KShares$83,4900.0% of portfolio
Latest Institutional Activity in NMTC
Top Purchases
Top Sells
About NMTC
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Insider Transactions at NMTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
906
-0.56%
|
$0
$0.89 P/Share
|
|
Sep 30
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-0.11%
|
$0
$0.89 P/Share
|
|
Sep 30
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,458
-0.21%
|
$0
$0.89 P/Share
|
|
Sep 05
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
30,000
-11.48%
|
$0
$0.74 P/Share
|
|
Jun 30
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-0.1%
|
$0
$0.68 P/Share
|
|
Jun 30
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
906
-0.56%
|
$0
$0.68 P/Share
|
|
Jun 30
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,458
-0.21%
|
$0
$0.68 P/Share
|
|
Jun 04
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.68%
|
$0
$0.58 P/Share
|
|
May 22
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
8,967
-3.2%
|
$0
$0.62 P/Share
|
|
May 21
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
14
-0.01%
|
$0
$0.65 P/Share
|
|
May 20
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
3,013
-1.06%
|
$0
$0.66 P/Share
|
|
May 19
2025
|
Mark Christianson Business Development Director |
SELL
Open market or private sale
|
Direct |
8,006
-2.75%
|
$0
$0.67 P/Share
|
|
Apr 04
2025
|
Ronald W. Mc Clurg Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
200,000
+31.05%
|
$0
$0.5 P/Share
|
|
Apr 04
2025
|
David A Rosa CEO and President |
BUY
Open market or private purchase
|
Direct |
100,000
+7.93%
|
$0
$0.5 P/Share
|
|
Mar 31
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
906
-0.55%
|
$0
$0.85 P/Share
|
|
Mar 31
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
253
-0.09%
|
$0
$0.85 P/Share
|
|
Mar 31
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,458
-0.23%
|
$0
$0.85 P/Share
|
|
Feb 18
2025
|
Steve Mertens Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,376
-4.3%
|
$7,376
$1.16 P/Share
|
|
Feb 18
2025
|
Mark Christianson Business Development Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,812
-0.62%
|
$1,812
$1.16 P/Share
|
|
Feb 18
2025
|
David A Rosa CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
71,325
-6.28%
|
$71,325
$1.16 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 83.3K shares |
|---|---|
| Open market or private purchase | 300K shares |
| Payment of exercise price or tax liability | 103K shares |
|---|---|
| Open market or private sale | 60K shares |